BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15583696)

  • 1. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.
    Memon AA; Sorensen BS; Melgard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2004 Dec; 91(12):2034-41. PubMed ID: 15583696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
    Memon AA; Sorensen SB; Nexo E
    Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
    Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
    Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
    Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer.
    Nielsen TO; Borre M; Nexo E; Sorensen BS
    BJU Int; 2015 Jan; 115(1):163-5. PubMed ID: 24467768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.
    Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M
    Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
    Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
    Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
    BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
    Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
    Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
    Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP
    Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.
    Nielsen TO; Friis-Hansen L; Poulsen SS; Federspiel B; Sorensen BS
    PLoS One; 2014; 9(4):e94606. PubMed ID: 24728052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
    Lipponen P; Eskelinen M
    Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
    Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
    Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
    Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
    Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
    Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
    Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.